Prostate adenocarcinoma cells release the novel proinflammatory polypeptide EMAP-II in response to stress.
The proinflammatory protein endothelial monocyte-activating polypeptide II (EMAP-II) was first detected in supernatants of murine tumor cells by virtue of its ability to stimulate endothelial-dependent coagulation in vitro. The purified protein has pleiotropic effects on endothelial cells, monocytes, and neutrophils; however, its function in vivo is unknown, and the mechanism whereby it is released from cells is poorly understood. We investigated the expression of EMAP-II in human prostate adenocarcinoma specimens by immunohistochemistry and in LNCaP and DU-145 human prostate adenocarcinoma cells by reverse transcription-PCR, flow cytometry, and Western blotting. We then examined the effects of chemical and physiological stress on release and processing of EMAP-II by LNCaP and DU-145 cells. These cells constitutively express a Mr 34,000 form of EMAP-II that is retained intracellularly. Exposure to agents that induce apoptosis or, in some cases, necrosis induces the release of the Mr 34,000 form and further processing to the Mr 27,000 and Mr 22,000 forms. Hypoxia, but not heat shock, is a potent inducer of release and processing of biologically active EMAP-II by LNCaP and DU-145 cells. We suggest that release of EMAP-II by prostate adenocarcinoma cells as a consequence of treatment with anticancer agents or as a result of constitutive hypoxia may potentiate the effects of those agents through the localized activation of host effector mechanisms.
Barnett
G
G
Cancer Research Campaign Department of Clinical Oncology, City Hospital, Nottingham, United Kingdom.
Jakobsen
A M
AM
Tas
M
M
Rice
K
K
Carmichael
J
J
Murray
J C
JC
D000230:Adenocarcinoma / Q000378:metabolism*; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D000968:Antimycin A / Q000494:pharmacology; D017209:Apoptosis; D015153:Blotting, Western; D015687:Cell Hypoxia; D016207:Cytokines; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005434:Flow Cytometry; D005947:Glucose / Q000494:pharmacology; D006801:Humans; D007150:Immunohistochemistry; D015759:Ionomycin / Q000494:pharmacology; D007476:Ionophores / Q000494:pharmacology; D008297:Male; D009336:Necrosis; D009363:Neoplasm Proteins / Q000096:biosynthesis*; D010455:Peptides / Q000378:metabolism*; D011467:Prostate / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000378:metabolism*; D016601:RNA-Binding Proteins / Q000096:biosynthesis*; D011994:Recombinant Proteins / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013312:Stress, Physiological; D019284:Thapsigargin / Q000494:pharmacology; D014407:Tumor Cells, Cultured
D000900:Anti-Bacterial Agents; D016207:Cytokines; D004791:Enzyme Inhibitors; D007476:Ionophores; D009363:Neoplasm Proteins; D010455:Peptides; D016601:RNA-Binding Proteins; D011994:Recombinant Proteins; C077219:small inducible cytokine subfamily E, member 1; D015759:Ionomycin; D000968:Antimycin A; D019284:Thapsigargin; D005947:Glucose